WO1995028177A1 - Composition medicinale destinee a traiter la dyskinesie tardive et utilisation de ladite composition - Google Patents
Composition medicinale destinee a traiter la dyskinesie tardive et utilisation de ladite composition Download PDFInfo
- Publication number
- WO1995028177A1 WO1995028177A1 PCT/JP1995/000736 JP9500736W WO9528177A1 WO 1995028177 A1 WO1995028177 A1 WO 1995028177A1 JP 9500736 W JP9500736 W JP 9500736W WO 9528177 A1 WO9528177 A1 WO 9528177A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- administration
- compound
- phosphodiesterase
- tardive dyskinesia
- inhibitory activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- composition for the treatment of tardive dyskinesia and its use
- the present invention relates to a novel pharmaceutical composition for treating tardive dyskinesia, which contains, as an active ingredient, a compound having an activity to inhibit the enzymatic action of phosphodiesterase, and use of the composition. About.
- Tardive Jisukinejia various drugs was primarily antipsychotic agents which act as an antagonist against dopa Mi emissions D 2 receptors dopa Mi down nervous system striatum in the brain It is a condition associated with chronic involuntary movements that occur on the face, head or trunk, especially in patients associated with long-term administration of schizophrenia drugs. The onset of this involuntary movement is seen several months to several years after the start of the administration of the above-mentioned antipsychotic. Occasionally, the disease may appear after a dose reduction or withdrawal of the antipsychotic drug and persists long after the drug is discontinued. Some of the involuntary movements are irreversible, or may not be completely cured.
- Harope Li Donore (ha l oper i do l) is Buchiro full et Bruno emissions based striatum of a compound in the brain of dopa Mi down nervous system dopa Mi emissions D 2 receptor antagonist
- haloperidol has been widely used clinically for nearly 40 years.
- long-term administration of haloperidol has the side effects of inducing late-onset dyskinesia. Something is well known.
- Abnormal movements caused by involuntary dyskinesia as described above appear mainly in the mouth, on the face, especially on the tongue * jaw muscles, and are characterized by muzzling movements. However, it may appear on the head, trunk, and limbs. Late-onset dyskinesia is neurologically classified as hyperpyramidal hyperactivity in the motor spinal central pathways that connect to the spinal motor neurons, and is also classified in the brain. It is thought to be caused by dysfunction of the striatum suppression mechanism. The problem to be solved clinically is that the abnormal movements of tardive dyskinesia persist after antipsychotic drug withdrawal, become chronic, and eventually have an incurable outcome. (I nada T, K. Ohn i sh i, M. Kami sada, G. atsuda, O.
- anti-Parkinson's disease drugs which are used to treat the acute phase of the extrapyramidal motility of the motor spinal central pathway, can cause delayed dyskinesia. Symptoms are observed to cause disappointment. In addition, after the onset of tardive dyskinesia, the symptoms of the disease are often transiently exacerbated, even if the administration of antipsychotics is stopped, and it takes a long time to reduce the symptoms. Or irreversible state.
- PDE phosphodiesterase
- cAMP cyclic nucleotides
- I, ox, I.IV, V subtypes of PDE from enzyme activity regulators and substrate specificity.
- PDEI, PDEI, and PDEH hydrolyze cAMP and cGMP (cyclic guanosine 13 ', 5'-phosphoric acid) almost equally (nonspecifically), but PD IV
- cAMP has high specificity
- PDEV has high specificity for cGMP.
- rolipram (Rolipram; 4- (3- (cyclopentyloxy) -14-methoxyphenyl) -12-pyrrolidinone) is a compound that inhibits the enzyme activity of PDE. It is known to be effective as a therapeutic agent for dementia due to cerebrovascular disorders (US Patent No. 5,059.612, European Patent Application Publication No.
- the present inventors have conducted a number of studies with the aim of developing a medicament effective for treating tardive dyskinesia. From a result of accumulation of these studies, induced current, the present inventors have found that delayed Jisukinejia are shorted with the effects of prolonged administration of antipsychotic agents which act as a dopa Mi emissions D 2 receptor antagonist could and this to confirm the conclusion of a place to cause a hypersensitivity state of been dopa Mi emissions D 2 receptors.
- the amount of cAMP produced from ATP by AC in the brain cells of patients with late-onset dyskinesia is controlled by G i through the action of endogenous dopamine in the brain.
- the present inventors have obtained the speculation that abnormally strong decrease was observed and that this was causing dyskinesia symptoms (involuntary movement). It has been reached.
- PDE phosphodiesterase
- cAMP cyclic nucleotides
- PDE inhibitors Compounds that have the activity of inhibiting the enzyme action of PDE (hereinafter sometimes simply referred to as PDE inhibitors) are known to increase cAMP levels in the brain when they migrate into the brain. Have been.
- Et al is, by the this you considering that it is a function of the physiological effects of PDE inhibitors is independent of the receptor of a neurotransmitter, dopa Mi emissions D 2 receptor hypersensitivity (super 'sensi ti (vity) state, the present inventors can expect that the administration of the PDE inhibitor can improve at the stage of secondary neurotransmission toward the normal state at the stage of normal neurotransmission. (For these reasons, we have now identified a PDE inhibitor that has the ability to cross the blood-brain barrier, and especially an inhibitor against PDE IV, as a treatment for tardive dyskinesia. To predict for the first time that it may be effective.
- the present inventors have proposed that the chemical name of the oral lipram (Rolipram; chemical name: (Soil) having selective inhibitory activity against PDE IV (cAMP specific PDE) ) — 4- (3— (cyclopentyloxy) -14-methoxyphenyl) -12—pyrrolidinone) and several other PDE inhibitors after long-term administration of rat haloperidol Tests used in the treatment of experimentally induced tardive dyskinesia models should be performed for the first time to confirm that these PDE inhibitors are indeed effective in treating tardive dyskinesia. And succeeded.
- enzymes for phosphodiesterase that hydrolyze cAMP Compounds with inhibitory activity can be used for long-term administration of antipsychotics, especially schizophrenia, which act as antagonists at the dopamine D2 receptor in the dopaminergic nervous system in the brain.
- antipsychotics especially schizophrenia, which act as antagonists at the dopamine D2 receptor in the dopaminergic nervous system in the brain.
- schizophrenia which act as antagonists at the dopamine D2 receptor in the dopaminergic nervous system in the brain.
- the present inventors have now found that it is effective for treating delayed tardive dyskinesia.
- the present inventors have proposed a treatment for tardive dyskinesia by mixing such a compound having PDE inhibitory activity with a conventional pharmaceutically acceptable solid or liquid carrier.
- a pharmaceutical composition for oral use and generally can be administered to a person in need of treatment for tardive dyskinesia by an oral or parenteral route.
- a compound having enzyme inhibitory activity against phosphodiesterase and capable of passing through the blood-brain barrier after administration is contained as an active ingredient.
- a pharmaceutical composition for treating tardive dyskinesia characterized by containing a combination of a physiologically acceptable carrier.
- the first pharmaceutical composition according to the present invention is a phosphodiesterase that specifically acts on cyclic adenosine 1 3 ′, 5′-phosphate (cAMP). It is preferable to contain a compound having an enzyme inhibitory activity against a certain phosphodiesterase IV and capable of crossing the blood-brain barrier after administration, such as rolipram, as an active ingredient.
- cAMP cyclic adenosine 1 3 ′, 5′-phosphate
- Compounds having an inhibitory activity include, in addition to the above-mentioned rolipram, propentofylline (Menolec Index 11th edition, code number 7823, chemical name is 3, 7 — dihydro 1 3 — methyl 1 1 (5 — oxohexyl) 1 7 — propyl 1 1 H — purine 1 2, 6 — dione), denbufirin (Denbufylline; Chemical substance name is 7 — (2-oxopropyl) 1-1,3 — di-n-butylxanthine).
- R 020-1724 Journal of Medicinal Chemistry, Vol. 34, No. 1, p.
- Theophylline code number 9212 of Merck's Index 11th edition, chemical names 3, 7-dihydro-1) , 3 — dimethyl ether 1 H—purin 1 2, 6 — dione), vinpo-cetine (Melkin Index 11th edition) Over de number 9894, chemicals name is Ebana menu two emissions - 14 Ichiriki Rubo phosphate Echirue ester), and IBMX (chemical name is 3 - Lee Seo-butyl - 1 - there is a main Chirukisa inches down) or the like.
- composition of the present invention containing the above-mentioned active ingredient compound can be formulated in various dosage forms by mixing a solid or liquid carrier commonly used in medicine with the active ingredient.
- concentration of a compound having the exemplified PDE inhibitory activity said can be used as active ingredient in pharmaceutical compositions that by the first of the present invention to inhibit 50% the enzymatic activity of Hosuhojiesutera over peptidase in vitro (IC 5. ) has the value Ri according of Retea in literature several that rather decoction previously published, the IC 5. The values are shown in Table 1 below, along with their references. table 1
- a compound having PDE inhibitory activity used as an active ingredient in the pharmaceutical composition for treating tardive dyskinesia according to the present invention.
- the substance is present in the mammalian brain and is a phosphodiesterase such as PDE that specifically acts on cAMP.
- a PDE inhibitor having an activity capable of selectively inhibiting IV enzyme activity is preferred.
- the strength of the inhibitory activity against phosphodiesterase of a compound having PDE inhibitory activity that can be used as an active ingredient in the present invention is as follows: Generally, a standard measurement of the enzyme inhibitory activity of an enzyme inhibitor in a test tube. It can be detected by the method.
- tardive dyskinesia is found in brain cells. If the inventor's assumption that this is due to an abnormal decrease in cAMP concentration in the present case is appropriate, if the onset of tardive dyskinesia is expected by long-term administration of an antipsychotic, By administering the compound having a phosphodiesterase inhibitory activity used in the present invention in advance of the onset of tardive dyskinesia, abnormal decrease in cAMP concentration in brain cells can be reduced. It is expected that this can prevent or prevent the onset of tardive dyskinesia.
- the dose of the first pharmaceutical composition to an adult is in the range of 0.001 to 1,000 mg in terms of the active ingredient compound per day in the case of oral administration.
- Formulation of a pharmaceutical composition containing an active ingredient having PDE inhibitory activity for use in the present invention is carried out by a usual method in the technical field of formulation.
- the dosage form for oral administration is not particularly limited, and may be, for example, tablets, granules, powders, capsules, etc.
- a binder, a disintegrant, a lubricant, a colorant, etc. tablets, coated tablets, granules, powders, capsules and the like can be made by a conventional method.
- the pharmaceutical composition of the present invention can be administered in the form of a solution or a dispersed suspension containing the active ingredient compound.
- the active ingredient having PDE inhibitory activity used in the present invention is administered in the form of a pharmaceutical composition such as an injection or an oral preparation mixed with an excipient or carrier.
- Pharmaceutically acceptable excipients or carriers The type and composition selected will depend on the route and mode of administration.
- water, alcohol or animal and vegetable oils such as soybean oil, mineral oil, sesame oil, or sesame oil, or synthetic oils are used as the liquid carrier.
- solid carriers include sugars such as maltose and sucrose, amino acids such as lysine, cellulose derivatives such as hydroxypropylcellulose, and polysaccharides such as cyclodextrin.
- Organic salts such as magnesium and magnesium stearate are used.
- the liquid carrier is generally a saline solution, various buffers, saccharide solutions such as glucose, inositol, mannitol, ethylene glycol, etc. And glycols such as polyethylene glycol. Lyophilized with excipients such as saccharides such as inositol, mannitol, glucose mannose, maltose and sucrose, and amino acids such as phenylalanine Formulated as a preparation and dissolved or dissolved in an appropriate solvent for injection at the time of administration, such as sterile water, saline, glucose solution, electrolyte solution, amino acid, etc. Can be used suspended.
- An appropriate surfactant can be added as a solubilizer to assist in dissolving the active ingredient compound.
- the content of the active ingredient in the formulated pharmaceutical composition varies depending on the dosage form. Usually, it is between 0.001 and 99% by weight, preferably between 0.01 and 90% by weight.
- the active ingredient compound is usually preferably contained in a content of 0.01 to 5% by weight.
- O 9 In the case of oral administration, O 9
- the content of the active ingredient compound is generally 0.01% to 99% by weight, 5 preferably 0.02% to 90% by weight, and the remainder is a carrier.
- the dose of the active ingredient used in the present invention is generally determined according to the age, weight, symptoms, treatment purpose, etc. of the patient. However, the dose may vary depending on the results of animal tests and the like. Continuous, as long as the total dose does not exceed a certain amount considering the situation
- It can be administered 10 or intermittently.
- the appropriate dosage and frequency of administration under certain conditions are determined by the specialist.
- long-term antipsychotic in particular schizophrenia therapeutic agents which act as an antagonist against dopa Mi emissions D 2 receptors dopa Mi down nervous system in the brain
- a compound that has enzyme inhibitory activity against phosphodiesterase, especially phosphodiesterase IV, and that can cross the blood-brain barrier after administration to patients who develop delayed onset dyskinesia and require treatment A method for treating tardive dyskinesia comprising administering a therapeutically effective amount of
- Another aspect of the present invention includes the use of a compound having an enzyme inhibitory activity against phosphodiesterase and capable of crossing the blood-brain barrier after administration in the production of a therapeutic agent for tardive dyskinesia. I do.
- a phosphodiester A delayed onset dyskinesia comprising mixing a compound having enzymatic inhibitory activity against esterases and capable of crossing the blood-brain barrier after administration with a pharmaceutically acceptable solid or liquid carrier.
- the present invention also encompasses a method for producing a pharmaceutical composition for the treatment of cancer.
- the active ingredient compound that can be preferably used in the present invention is oral ribram.
- Rolipram is a selective inhibitor of cAMP-specific phosphodiesterase, and is known to increase cAMP levels in rat brain in animal studies (see Journal of edicinal Chemistry J 34: 1, 291-293 (1991)).
- Haloperidol was intraperitoneally administered to SD rats (male, 6 per group) once daily at a dose of 1.5 mg kg for 3 weeks. At 96 hours after the completion of the administration, the number of appearances of the rat's silent chewing and abnormal tongue protrusions was determined by the late onset dyskinesia. It was measured as an indicator of the symptoms of the disease.
- Mouth lipum given at doses of 0.5 mgZkg and 1.OmgZiig mimics the symptoms of an experimental model of tardive dyskinesia caused by continuous administration of lipperidone to rats. It is shown that the treatment effect was suppressed in a dose-dependent manner.
- Test example 2
- SD rats male, 6 per group were injected intramuscularly with haloperidol • decanoate at a dose of SSmgZ kg once every four weeks for 24 weeks over the thighs.
- test rats Eight weeks after the last dose of haloperidol decanoate, these test rats were partially dissolved with oral ribulum or IBMX in a saline solution containing 10% cremophor. It was administered intraperitoneally as a thawed and partially dispersed suspension. Rats in the negative control group received only saline containing 10% cremophor.
- SD rats female, 7 to 8 animals per group
- a 1.5% Zkg dose of noroperidol as a 0.5% strength ruboxyl methylcellulose suspension once daily for 5 consecutive weeks. It was repeatedly administered intraperitoneally.
- R020-1724 was administered to these test rats at a dose of 3, 10, or 30 mg / kg in a saline solution containing 10% Cremophor.
- the suspension was administered intraperitoneally as a partially dissolved and partially dispersed suspension.
- Rats in the negative control group received only physiological saline containing 10% cremophor.
- a novel medicament for treating or preventing tardive dyskinesia which comprises, as an active ingredient, a compound having an enzyme inhibitory activity against phosphogesterase.
- a composition is provided. This pharmaceutical composition is useful for suppressing the symptoms of tardive dyskinesia and can provide a new method for treating or preventing tardive dyskinesia.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019960705701A KR970702037A (ko) | 1994-04-15 | 1995-04-14 | 지발성 디스키네시아의 치료용 의약 조성물과 이의 용도 기술분야 |
EP95915324A EP0755685A4 (en) | 1994-04-15 | 1995-04-14 | PHARMACEUTICAL COMPOSITION FOR TREATING LATE DYSKINESIA |
AU22241/95A AU2224195A (en) | 1994-04-15 | 1995-04-14 | Medicinal composition for treating tardive dyskinesia and utilization thereof |
US08/727,654 US5712282A (en) | 1994-04-15 | 1995-04-14 | Method for therapeutically treating tardive dyskinesia and uses thereof |
JP52686595A JP3598116B2 (ja) | 1994-04-15 | 1995-04-14 | 遅発性ジスキネジアの治療用医薬組成物とその利用 |
NO964330A NO964330D0 (no) | 1994-04-15 | 1996-10-11 | Farmasöytisk sammensetning for terapeutisk behandling av tardiv dyskinesi og anvendelse derav |
FI964113A FI964113A (fi) | 1994-04-15 | 1996-10-14 | Lääkekoostumus hoitamaan tardiivia dyskinesiaa ja sen käyttö |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6/77146 | 1994-04-15 | ||
JP7714694 | 1994-04-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995028177A1 true WO1995028177A1 (fr) | 1995-10-26 |
Family
ID=13625663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1995/000736 WO1995028177A1 (fr) | 1994-04-15 | 1995-04-14 | Composition medicinale destinee a traiter la dyskinesie tardive et utilisation de ladite composition |
Country Status (8)
Country | Link |
---|---|
US (1) | US5712282A (ja) |
EP (1) | EP0755685A4 (ja) |
JP (1) | JP3598116B2 (ja) |
AU (1) | AU2224195A (ja) |
CA (1) | CA2187086A1 (ja) |
FI (1) | FI964113A (ja) |
NO (1) | NO964330D0 (ja) |
WO (1) | WO1995028177A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020099003A1 (en) | 1997-10-28 | 2002-07-25 | Wilson Leland F. | Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof |
US6268352B1 (en) * | 1998-09-02 | 2001-07-31 | The Regents Of The University Of California | Promoters of neural regeneration |
WO2001032170A1 (en) * | 1999-09-13 | 2001-05-10 | Swope David M | Composition and method for decreasing neurologic symptomatology |
EP1343528A2 (en) * | 2000-11-02 | 2003-09-17 | Research Foundation of City University of New York | Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 |
IL149106A0 (en) * | 2001-04-20 | 2002-11-10 | Pfizer Prod Inc | Therapeutic use of selective pde10 inhibitors |
CA2471147C (en) * | 2002-01-04 | 2010-08-10 | Henry Ford Health System | Nitric oxide donors for treatment of disease and injury |
US20060111368A1 (en) * | 2002-06-26 | 2006-05-25 | Kyowa Hakko Kogyo Co., Ltd. | Phosphodiesterase inhibitor |
EP1850852A4 (en) * | 2005-02-22 | 2009-11-18 | Cedars Sinai Medical Center | USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO INCREASE THE PERMEABILITY OF THE ABNORMAL BLOOD-BRAIN DISEASE |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59148748A (ja) * | 1983-02-10 | 1984-08-25 | Takeda Chem Ind Ltd | ノナペプチド |
JPS63238054A (ja) * | 1987-03-04 | 1988-10-04 | サンド・アクチエンゲゼルシャフト | フェニルカルバメート |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2578001B2 (ja) * | 1989-12-11 | 1997-02-05 | 明治製菓株式会社 | 抗痴呆薬 |
-
1995
- 1995-04-14 WO PCT/JP1995/000736 patent/WO1995028177A1/ja not_active Application Discontinuation
- 1995-04-14 AU AU22241/95A patent/AU2224195A/en not_active Abandoned
- 1995-04-14 EP EP95915324A patent/EP0755685A4/en not_active Withdrawn
- 1995-04-14 CA CA002187086A patent/CA2187086A1/en not_active Abandoned
- 1995-04-14 US US08/727,654 patent/US5712282A/en not_active Expired - Lifetime
- 1995-04-14 JP JP52686595A patent/JP3598116B2/ja not_active Expired - Lifetime
-
1996
- 1996-10-11 NO NO964330A patent/NO964330D0/no not_active Application Discontinuation
- 1996-10-14 FI FI964113A patent/FI964113A/fi unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59148748A (ja) * | 1983-02-10 | 1984-08-25 | Takeda Chem Ind Ltd | ノナペプチド |
JPS63238054A (ja) * | 1987-03-04 | 1988-10-04 | サンド・アクチエンゲゼルシャフト | フェニルカルバメート |
Non-Patent Citations (1)
Title |
---|
See also references of EP0755685A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP0755685A4 (en) | 2000-05-03 |
AU2224195A (en) | 1995-11-10 |
US5712282A (en) | 1998-01-27 |
FI964113A0 (fi) | 1996-10-14 |
EP0755685A1 (en) | 1997-01-29 |
CA2187086A1 (en) | 1995-10-26 |
JP3598116B2 (ja) | 2004-12-08 |
NO964330L (no) | 1996-10-11 |
NO964330D0 (no) | 1996-10-11 |
FI964113A (fi) | 1996-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2221563C2 (ru) | Фармацевтическая композиция для лечения болезни паркинсона и синдромов паркинсона, способ ее получения, способ лечения болезни паркинсона и синдромов паркинсона | |
TWI222867B (en) | Pharmaceutical compositions for treating hepatitis virus infections n-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds | |
KR20070036079A (ko) | 성기능 장애에 관한 다중 제제 요법 | |
US20060035911A1 (en) | Method of improved diuresis in individuals with impaired renal function | |
WO2005094885A1 (ja) | 慢性筋骨格痛を呈する疾患の予防および/または治療剤 | |
EP1874293A1 (fr) | Association entre la ferroquine et un derive d artemisinine pour le traitement du paludisme | |
US20060293312A1 (en) | Method of improved diuresis in individuals with impaired renal function | |
AU5198301A (en) | The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease | |
US20020002145A1 (en) | Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver | |
WO1995028177A1 (fr) | Composition medicinale destinee a traiter la dyskinesie tardive et utilisation de ladite composition | |
CA2568436A1 (en) | Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor | |
KR20050106038A (ko) | 심장질환 및 신장질환의 치료를 위한 아데노신 a1 수용체길항제 | |
CA2362918A1 (en) | Methods and compositions for treating erectile dysfunction | |
JP3415643B2 (ja) | 筋ジストロフィー症治療薬 | |
EP1084704B1 (en) | Remedies for spinocerebellar ataxia and compositions for treating spinocerebellar ataxia | |
JPH0352816A (ja) | 腎炎の治療剤 | |
JP3276762B2 (ja) | イソキノリン誘導体を含有する医薬組成物 | |
CA2521274A1 (en) | Combinations comprising anti-epileptic drugs for the treatment of neurological disorders | |
MXPA06013814A (es) | Terapia de agentes multiples para la disfuncion sexual. | |
JP7068474B2 (ja) | ビクテグラビルの代謝物 | |
JP4747579B2 (ja) | アトピー性皮膚炎の予防・治療剤 | |
JP6280050B2 (ja) | 肥満症予防又は治療剤,リウマチの予防又は治療剤 | |
JPH10279497A (ja) | β−アミノ酸吸収抑制剤 | |
JPH11246408A (ja) | 肝障害治療剤 | |
JPH06211657A (ja) | 尿酸排泄剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CH CN DE DK ES FI GB HU JP KR NO PL RU SE SG UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2187086 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995915324 Country of ref document: EP Ref document number: 08727654 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 964113 Country of ref document: FI |
|
WWP | Wipo information: published in national office |
Ref document number: 1995915324 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995915324 Country of ref document: EP |